Overview Request Sample Pages Request Customization Download PDF
You are viewing: Rest Of Asia Pacific Preimplantation Genetic Testing Market analysis

The Rest Of Asia Pacific Preimplantation Genetic Testing Market was valued at $13.1 Million in 2025 and projected to reach to $22.7 Million by 2030, representing a compound annual growth rate of 11.6%. Rest Of Asia Pacific's preimplantation genetic testing market is positioned for sustained growth through 2030, supported by expanding fertility clinic networks and increasing healthcare investments in reproductive medicine.

Rest Of Asia Pacific Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Asia Pacific Preimplantation Genetic Testing Market Trends and Insights

  • Rest Of Asia Pacific's growth trajectory reflects increasing adoption of advanced reproductive technologies and rising awareness of genetic screening benefits among fertility clinics and patients.
  • The region's 11.6% compound annual growth rate outpaces global benchmarks, driven by improving healthcare infrastructure, growing disposable incomes, and expanding access to assisted reproductive services across emerging markets. Rest Of Asia Pacific's market dynamics are shaped by regulatory developments, technological innovations in genetic sequencing, and shifting demographic patterns favoring delayed parenthood.
  • Rest Of Asia Pacific demonstrates significant potential as healthcare providers invest in PGT capabilities and patient education initiatives gain momentum.
  • The forecast period through 2030 positions Rest Of Asia Pacific as a high-growth region within the broader Asia Pacific landscape, with expanding clinical adoption and increasing reimbursement recognition supporting market acceleration..

Key Market Statistics

  • CAGR (2025-2030) 11.6% CAGR
  • Market Size, 2025 ~USD 13.1 Million
  • Forecast, 2030 ~USD 22.7 Million
  • Country Rest Of Asia Pacific

Rest Of Asia Pacific Preimplantation Genetic Testing Market Overview

Strong Regional Growth :

Rest Of Asia Pacific's PGT market is expanding at 11.6% CAGR, outpacing the global average of 10.5%, driven by increasing fertility clinic adoption and patient demand for genetic screening services.

Market Valuation Trajectory :

The market is valued at USD 13.1 million in 2025 and is projected to grow to USD 22.7 million by 2030, representing a 73% increase over the five-year forecast period.

Rising Reproductive Technology Adoption :

Fertility clinics across Rest Of Asia Pacific are increasingly integrating advanced PGT technologies, reflecting growing awareness among healthcare providers about genetic screening benefits and improved patient outcomes.

Patient Awareness and Demand :

Growing consciousness among patients regarding genetic health risks and reproductive options is fueling demand for preimplantation genetic testing services across the region's emerging and developing markets.

Rest Of Asia Pacific Preimplantation Genetic Testing Market Dynamics

  • The region's developing economies are witnessing rising disposable incomes and improved access to advanced diagnostic technologies, enabling broader adoption of PGT services among middle-class populations seeking enhanced reproductive outcomes. Key growth drivers include enhanced awareness campaigns, regulatory support for assisted reproductive technologies, and partnerships between international PGT providers and regional fertility centers.
  • As healthcare infrastructure improves and genetic testing becomes more affordable, Rest Of Asia Pacific is expected to emerge as a significant growth contributor to the global PGT market, with particular momentum in Southeast Asian and South Asian markets..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Rest Of Asia Pacific's PGT market is valued at USD 13.1 million in 2025, with projected growth to USD 22.7 million by 2030, representing an 11.6% CAGR.
      • Rest Of Asia Pacific's growth rate exceeds global averages, driven by improving healthcare infrastructure and rising fertility treatment demand across emerging economies.
      • Rest Of Asia Pacific benefits from increasing patient awareness, technological advancement in genetic sequencing, and expanding fertility clinic capabilities.
      • Rest Of Asia Pacific's market expansion is supported by favorable demographic trends, growing disposable incomes, and emerging reimbursement pathways through 2030.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Rest Of Asia Pacific Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      Target Audience

      • Fertility Clinic Operators : Need regional market data to evaluate PGT service expansion opportunities, benchmark against competitors, and make informed capital allocation decisions for technology adoption.
      • PGT Technology Providers : Require detailed market intelligence on Rest Of Asia Pacific demand patterns, competitive positioning, and growth forecasts to develop region-specific go-to-market strategies.
      • Healthcare Investment Firms : Seek comprehensive market analysis and growth projections for Rest Of Asia Pacific to identify attractive investment targets in reproductive medicine and genetic testing sectors.
      • Medical Device & Diagnostics Companies : Need regional market sizing and trend analysis to assess commercial viability of PGT solutions and plan product launches in Rest Of Asia Pacific markets.
      • Healthcare Policy & Regulatory Bodies : Require market data and adoption trends to inform regulatory frameworks, reimbursement policies, and healthcare infrastructure planning for reproductive genetic testing services.

      Key Companies in the Rest Of Asia Pacific Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Regional Market Sizing & Forecasts : Obtain precise valuation data specific to Rest Of Asia Pacific (USD 13.1M in 2025, USD 22.7M in 2030) with detailed CAGR analysis to support strategic planning and investment decisions.
      • Competitive Landscape Intelligence : Understand key players, market share distribution, and competitive strategies within Rest Of Asia Pacific's PGT sector to identify partnership and expansion opportunities.
      • Growth Driver Analysis : Gain insights into region-specific factors driving 11.6% CAGR, including fertility clinic expansion, patient awareness trends, and regulatory developments unique to Rest Of Asia Pacific markets.
      • Market Entry & Expansion Strategy : Access actionable recommendations for market penetration, localization strategies, and customer acquisition approaches tailored to Rest Of Asia Pacific's diverse healthcare ecosystems.
      • Emerging Opportunity Identification : Identify high-potential sub-markets and underserved segments within Rest Of Asia Pacific where PGT adoption is accelerating and investment returns are maximized.

      Frequently asked questions

      What is the current market size of PGT in Rest Of Asia Pacific?

      Rest Of Asia Pacific's Preimplantation Genetic Testing market is valued at USD 13.1 million in 2025.

      What is the projected market size for Rest Of Asia Pacific by 2030?

      Rest Of Asia Pacific's PGT market is forecast to reach USD 22.7 million by 2030.

      What is the CAGR for Rest Of Asia Pacific's PGT market?

      Rest Of Asia Pacific's Preimplantation Genetic Testing market is growing at a compound annual growth rate of 11.6% from 2025 to 2030.

      What factors are driving growth in Rest Of Asia Pacific's PGT market?

      Rest Of Asia Pacific's market growth is driven by improving healthcare infrastructure, rising fertility treatment demand, increasing patient awareness, technological advancement, and expanding clinic capabilities.

      How does Rest Of Asia Pacific's PGT market compare to global growth?

      Rest Of Asia Pacific's 11.6% CAGR exceeds the global average of 10.5%, positioning the region as a high-growth market within the broader industry landscape.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status